Christopher Hocking

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Robert J. Motzer, Thomas Powles, Mauricio Burotto et al. · The Lancet Oncology · 2022 · 307 citations · Full text

Medicine, Oncology, Pharmacology +10

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Chris Parker, Noel W. Clarke, Adrian Cook et al. · The Lancet · 2024 · 49 citations · Full text

Medicine, Oncology, Surgery +15

The effect of blinks and saccadic eye movements on visual reaction times

Murray W. Johns, Kate Crowley, Robert J. Chapman et al. · Attention Perception & Psychophysics · 2009 · 41 citations · Full text

Life Sciences, Neuroscience, Psychology +14

Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer

Maressa A. Bruhn, Amanda Townsend, Chee Khoon Lee et al. · International Journal of Cancer · 2013 · 32 citations

Medicine, Oncology, Pharmacology +17